 Mustang Bio NASDAQ:MBIO was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, Mustang Bio, Inc. a subsidiary of Fortress Biotech, Inc., is a clinical?stage biopharmaceutical company. It focused on the development and commercialization of ... 